Advancing Vision Care: Our Pipeline
Innovative Solutions for Global Vision Challenges
TECLens is dedicated to improving vision care with innovative technology. Unlike other cross-linking techniques, the qCXL™ technology has the potential to treat refractive errors in patients with healthy corneas.
Globally, at least 1 billion people have near or distance vision impairment that could have been prevented or has yet to be addressed. TECLens’ innovation has the potential to significantly improve access to care for some of the world’s most complex vision correction needs.
Our pipeline includes promising solutions for a variety of indications. Our qCXL™ technology is initially focused on addressing refractive errors, including presbyopia, with possible expansion into keratoconus, pediatric myopia, low-order adult myopia, and hyperopia.
Target Indications:
Presbyopia
Progressive Pediatric Myopia
Keratoconus
Hyperopia
Low-order Myopia
Presbyopia
Presbyopia is the inability to read up close caused by loss of elasticity of the natural lens with age. It affects nearly everyone over the age of 40.
CXLens® was designed to accurately correct presbyopia by gently strengthening and reshaping the cornea to add refractive power lost to natural lens stiffness. Presbyopia affects over 120 million Americans1 representing a $14.5B opportunity in the U.S. By the year 2030, 2.1B patients around the globe are expected to be affected by presbyopia.2
Control of Progressive Pediatric Myopia
Myopia (nearsightedness) is a global public health crisis. By 2050, nearly 5 billion people or 1 out of every 2 people on earth will suffer from myopia.3 In the U.S., myopia cases have increased 66% since 1971. Today in East and Southeast Asia, in countries such as South Korea, Taiwan, Singapore, China, and Japan, the prevalence of myopia is 80-90% among urban teenagers.4
We believe that qCXL™ will be able to treat young children to help control myopia progression. We feel qCXL can gently strengthen and reshape the cornea to reduce the peripheral hyperopia that drives myopia progression, while eliminating the underlying myopic error. This could potentially free millions of young patients from dependency on glasses and the risks of pathologic myopia. Unlike orthokeratology and bifocal contact lenses which require long term daily use, we believe that CXL can offer a permanent one-time treatment to slow myopia progression.
Keratoconus
Keratoconus (KCN) is a progressive eye disease in which the normally round cornea thins and begins to bulge into a cone-like shape necessitating a corneal transplant in 1 out of 5 patients. Keratoconus affects about 1 in 375 people in western populations or about 650,000.5
CXLens® has been shown to arrest the progression of KCN. The TECLens control console for keratoconus can drive two CXLens® devices at once to treat both eyes simultaneously.
References:
- American Optometric Association. August 2023.
- Katz, James A., et al. “Presbyopia – A Review of Current Treatment Options and Emerging Therapies.” Clinical Ophthalmology, vol. 15, 24 May 2021, pp. 2167-2178. PubMed Central, doi:10.2147/OPTH.S259011.
- The International Agency for the Prevention of Blindness. “Half the world to be short-sighted by 2050.” 02 Dec 2016
- Holden, Brien A., et al. “Myopia: A Growing Global Problem with Sight-Threatening Complications.” National Library of Medicine. Community Eye Health, vol. 28, no. 90, 2015, p. 35. PubMed Central, www.ncbi.nlm.nih.gov/pmc/articles/PMC4675264/.
- Specialty Vision.”Keratoconus: A New Study Indicates That It Is More Common and Concerning in the United States Than Previously Believed” 06 June 2023
Learn About Our Team
technology, understand our pipeline, and join us on this exciting journey to
reshape the future of vision care.